Experiment 1115136

Details

PropertyValue
Pharmacology
Administration routeIV
OrganismEmpty organism
CitationKELSEN,D: GRALLA,R: CHENG,E: MARTINI,N:. (1983). VINDESINE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA: A PHASE II STUDY.. 67(9)
Amount utilized
Compound isolated
DiseaseA PHASE II TRIAL OF VINDESINE WAS PERFORMED IN PATIENTS WITH ADVANCED MALIGNANT MESOTHELIOMA. THE DRUG WAS GIVEN AT A DOSE OF 3 MG/SQ M ONCE WEEKLY FOR 4-6 WEEKS AND THEN EVERY 2 WEEKS THEREAFTER. ONLY ONE OF 17 EVALUABLE PATIENTS HAD A PARTIAL REMISSION,LASTING 5 MONTHS. TOXIC EFFECTS INCLUDED LEUKOPENIA,PERIPHERAL NEUROPATHY AND ALOPECIA. IT WAS CONCLUDED THAT VINDESINE HAS MINIMAL ACTIVITY IN MALIGNANT MESOTHELIOMA.
Dose amount3.0 MG
Number1
Qualitative resultEQUIVOCAL
AnimalHUMAN ADULT
Per unitSQ M BODY SURFACE
Dose expressionDOSE